中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

136 records (took 0.017 seconds)

    IMMUNE MODULATION USING PEPTIDES AND OTHER COMPOSITIONS
    2.
    发明申请
    IMMUNE MODULATION USING PEPTIDES AND OTHER COMPOSITIONS 审中-公开
    使用肽和其他组合物的免疫调节

    公开(公告)号：WO2014160145A2

    公开(公告)日：2014-10-02

    申请号：PCT/US2014/025913

    申请日：2014-03-13

    Applicant: TRANSDERMAL BIOTECHNOLOGY, INC.

    Inventor： PERRICONE, Nicholas, V.

    IPC: A61K38/22

    CPC classification number: A61K33/00 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/10 ,  A61K38/09 ,  A61K38/22 ,  A61K38/34 ,  A61K47/14 ,  A61K47/186 ,  A61K47/24 ,  A61K47/36 ,  A61K47/48084 ,  A61K47/548 ,  A61K2300/00

    Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery for immune modulation. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid "stick," etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

    Abstract translation: 本发明一般涉及用于免疫调节的局部或经皮递送的组合物和方法。 在一些情况下，组合物可以包含一氧化氮和/或肽，例如促甲状腺激素释放激素（TRH）和/或GnRH（促性腺激素释放激素）。 一氧化氮和/或肽可以存在于包含卵磷脂例如磷脂酰胆碱的第一相中。 在某些实施方案中，卵磷脂存在于脂质体，胶束或含有一氧化氮，肽或二者的其他结构中。 该组合物可以采取凝胶，乳膏，洗剂，软膏，溶液，固体“棒”的形式。 可以摩擦或喷洒到皮肤上。 本发明的其它方面通常涉及制备或使用这样的组合物的方法，促进这种组合物的方法，包含这种组合物的试剂盒等。

    METHODS AND SYSTEMS FOR TREATING OR PREVENTING CANCER
    3.
    发明申请
    METHODS AND SYSTEMS FOR TREATING OR PREVENTING CANCER 审中-公开
    治疗或预防癌症的方法和系统

    公开(公告)号：WO2014160070A2

    公开(公告)日：2014-10-02

    申请号：PCT/US2014/025758

    申请日：2014-03-13

    Applicant: TRANSDERMAL BIOTECHNOLOGY, INC.

    Inventor： PERRICONE, Nicholas, V.

    IPC: A61K38/22

    CPC classification number: A61K38/34 ,  A61K9/0014 ,  A61K33/00 ,  A61K38/066 ,  A61K38/09 ,  A61K38/22 ,  A61K2300/00

    Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of cancer or other conditions. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid "stick," etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

    Abstract translation: 本发明总体上涉及用于治疗患有或具有癌症或其它病症风险的受试者的组合物和方法。 在一些情况下，组合物可以包括一氧化氮和/或肽，例如促甲状腺激素释放激素（TRH）和/或GnRH（促性腺激素释放激素）。 一氧化氮和/或肽可以存在于包含卵磷脂（例如磷脂酰胆碱）的第一相内。 在某些实施方案中，卵磷脂存在于含有一氧化氮的脂质体，胶束或其它结构中。 组合物可以采用可以被摩擦或喷到皮肤上的凝胶，乳膏，洗剂，软膏，溶液，固体“棒”等的形式。 本发明的其它方面一般涉及制备或使用这种组合物的方法，促进这种组合物的方法，包括这种组合物的试剂盒等。

    BREMELANOTIDE THERAPY FOR FEMALE SEXUAL DYSFUNCTION
    4.
    发明申请
    BREMELANOTIDE THERAPY FOR FEMALE SEXUAL DYSFUNCTION 审中-公开
    女性性功能障碍的BREMELANOTIDE治疗

    公开(公告)号：WO2014071339A3

    公开(公告)日：2014-06-12

    申请号：PCT/US2013068386

    申请日：2013-11-05

    Applicant: PALATIN TECHNOLOGIES INC

    Inventor： SPANA CARL ,  JORDAN ROBERT ,  EDELSON JEFFREY D

    IPC: A61K38/12 ,  A61P15/00 ,  C07K7/64

    CPC classification number: A61K38/12 ,  A61K31/4178 ,  A61K38/34

    Abstract: Use of a subcutaneously administered dose of between about 1,0 mg and 175 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.

    Abstract translation: 使用皮下施用剂量的约1,0mg至175mg的bremelanotide或其药学上可接受的米曲坦紫杉醇盐用于治疗女性的女性性功能障碍，同时减少或最小化不期望的副作用。

    SHORT ANTIMICROBIAL LIPOPEPTIDES
    5.
    发明申请
    SHORT ANTIMICROBIAL LIPOPEPTIDES 审中-公开
    短期抗精神病药

    公开(公告)号：WO2013142088A1

    公开(公告)日：2013-09-26

    申请号：PCT/US2013/029696

    申请日：2013-03-07

    Applicant: HELIX BIOMEDIX INC

    Inventor： ZHANG, Lijuan ,  CARMICHAEL, Robin

    IPC: A61K47/48 ,  C07K5/09 ,  A61K38/34

    CPC classification number: C07K5/06086 ,  A61K38/05 ,  A61K38/06 ,  A61K38/34 ,  A61K47/542 ,  C07K5/0815 ,  Y02A50/473

    Abstract: Disclosed are peptides having biological and therapeutic activity. Particularly disclosed are lipidated di- or tri- peptides analogs of KPV or KdPT that exhibit antimicrobial activity. In particular, the peptides of this invention provide enhanced anti-microbial activity over the base tri -peptides, lysine -proline- valine and lysine-d-proline-tyrosine. The disclosed peptides have the general formula of C12-18 lipid— KXZ-NH 2 i wherein K is lysine; X is proline, d-proline, histidine or arginine; Z is optional and if present Z is valine, threonine, alanine or leucine; and the terminal COOH is NH 2 amidated. The C12-18 lipid is preferably the lipid moiety of lauric acid (C12), myristic acid (C14), pentadecanoic acid (C15), palmitic acid (C16), or stearic acid (C18). The invention is further related to methods of using of these peptides to treat various insults, inflammations or bacterial infections affecting the skin and other related mucosal body surfaces such as the oral cavity.

    Abstract translation: 公开了具有生物和治疗活性的肽。 特别公开了表现出抗微生物活性的KPV或KdPT的脂化二或三肽类似物。 特别地，本发明的肽相对于碱基三肽，赖氨酸 - 脯氨酸 - 缬氨酸和赖氨酸-d-脯氨酸 - 酪氨酸提供增强的抗微生物活性。 所公开的肽具有通式C12-18脂质KXZ-NH2i，其中K是赖氨酸; X是脯氨酸，脯氨酸，组氨酸或精氨酸; Z是任选的，如果存在Z是缬氨酸，苏氨酸，丙氨酸或亮氨酸; 并且末端COOH是NH 2酰胺化的。 C12-18脂质优选为月桂酸（C12），肉豆蔻酸（C14），十五烷酸（C15），棕榈酸（C16）或硬脂酸（C18）的脂质部分。 本发明还涉及使用这些肽来治疗影响皮肤和其它相关粘膜体表如口腔的各种侮辱，炎症或细菌感染的方法。

    TRIPEPTIDE KDPT FOR ANTIAPOPTOTIC TREATMENT
    7.
    发明申请
    TRIPEPTIDE KDPT FOR ANTIAPOPTOTIC TREATMENT 审中-公开
    TRIPEPTIDE KDPT用于抗病毒治疗

    公开(公告)号：WO2013041719A1

    公开(公告)日：2013-03-28

    申请号：PCT/EP2012/068755

    申请日：2012-09-24

    Applicant: WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER ,  BETTENWORTH, Dominik ,  BOEHM, Markus ,  LUEGERING, Andreas

    Inventor： BETTENWORTH, Dominik ,  BOEHM, Markus ,  LUEGERING, Andreas

    IPC: A61K38/06 ,  A61P1/00 ,  A61P17/00 ,  A61P25/28 ,  A61P9/00 ,  A61K38/34

    CPC classification number: C07K5/0815 ,  A61K38/06 ,  A61K38/34

    Abstract: The present invention is related to the tripeptide (l)Lys-(d)Pro-(l)Thr (KdPT) or pharmaceutically acceptable salts thereof for therapeutic, prophylactic therapeutic or cosmetic treatment of a disease with increased apoptosis, wherein the treatment has an anti- apoptotic effect. The present invention is also related to the use of KdPT or pharmaceutically acceptable salts thereof for the manufacture of a pharmaceutical or cosmetic composition for an anti-apoptotic treatment of disorders that are related with increased apoptosis.

    Abstract translation: 本发明涉及三肽（1）Lys-（d）Pro-（1）Thr（KdPT）或其药学上可接受的盐，用于治疗，预防性治疗或美容治疗具有增加的细胞凋亡的疾病，其中治疗具有 抗凋亡作用。 本发明还涉及KdPT或其药学上可接受的盐在制备用于与凋亡增加相关的疾病的抗凋亡治疗的药物或化妆品组合物中的用途。

    PHARMACEUTICAL COMPOSITIONS OF MELANOCORTIN RECEPTOR LIGANDS
    8.
    发明申请
    PHARMACEUTICAL COMPOSITIONS OF MELANOCORTIN RECEPTOR LIGANDS 审中-公开
    梅毒素受体配体的药物组合物

    公开(公告)号：WO2011060352A1

    公开(公告)日：2011-05-19

    申请号：PCT/US2010/056690

    申请日：2010-11-15

    Applicant: IPSEN PHARMA S.A.S. ,  DONG, Zheng Xin ,  ZHANG, Jundong

    Inventor： DONG, Zheng Xin ,  ZHANG, Jundong

    IPC: A01N25/00

    CPC classification number: A61K38/33 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/08 ,  A61K38/34 ,  C07K14/68 ,  C07K14/69

    Abstract: The present invention relates to improvements in compositions containing peptides that are ligands of one or more of the melanocortin receptors (MC-R), or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of Ac-Arg-cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH 2 which is a ligand of the melanocortin receptor subtype 4 (MC4-R), and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms a depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol (PEG) with an average molecular weight of lower than 1000.

    Abstract translation: 本发明涉及包含作为一种或多种黑皮质素受体（MC-R）的配体的肽或其药学上可接受的盐的组合物的组合物的改进，以及使用这些组合物治疗哺乳动物的方法。 特别地，本发明涉及包含作为黑皮质素受体的配体的Ac-Arg-环（Cys-D-Ala-His-D-Phe-Arg-Trp-Cys）-NH 2的双羟萘酸盐的药物组合物 亚型4（MC4-R），并且其中在对受试者皮下或肌肉内施用后，肽在生理pH下形成缓慢溶解并释放到体液和血流中的贮库。 本发明还可以包含平均分子量低于1000的有机组分如二甲基乙酰胺（DMA）或聚乙二醇（PEG）。

Patent Agency Ranking